- The FDA has approved Sanofi's SA SNY Nexviazyme (avalglucosidase alfa-ngpt) to treat patients one year of age and older with late-onset Pompe disease.
- Pompe disease is a progressive and debilitating muscle disorder that impairs a person's ability to move and breathe.
- Nexviazyme is an enzyme replacement therapy (ERT) designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of enzyme replacement therapy in Pompe disease.
- Price Action: SNY shares are up 0.2% at $50.66 during the market session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
